View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
December 20, 2011

Novartis concludes Altitude study with Rasilez/Tekturna

Novartis has decided to conclude the Altitude study with Rasilez/Tekturna (aliskiren), on the recommendation of the independent data monitoring committee overseeing the trial.

Novartis Head quarters

Novartis has decided to conclude the Altitude study with Rasilez/Tekturna (aliskiren), on the recommendation of the independent data monitoring committee overseeing the trial.

The committee said that patients receiving Rasilez/Tekturna were unlikely to benefit from treatment added on top of standard anti-hypertensives, and identified higher adverse events compared to the standard of care.

In the first randomised, double-blind and placebo-controlled Phase III Altitude study, patients with type 2 diabetes and renal impairment were given Rasilez/Tekturna along with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker.

The trial arm in which Rasilez/Tekturna was added to the standard of care showed an increased incidence after 18-24 months of non-fatal stroke, renal complications, hyperkalemia and hypotension in the high-risk study population.

The company is in a dialogue with health authorities worldwide about the implications of the findings from Altitude for patients, and as a precautionary measure it will stop promoting Rasilez/Tekturna-based products for use in combination with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker.

Study investigators have been recommended to remove Rasilez/Tekturna-based products from patients’ treatment regimens and review their high blood pressure medication by Novartis.

The company said total sales of Rasilez/Tekturna-based products for the first nine months of 2011 were $449m, and are expected to be negatively impacted by the study results.

In previous clinical studies, the efficacy and safety of Rasilez/Tekturna have been investigated in more than 57,000 patients.

Caption: Novartis terminates clinical study with Rasilez/Tekturna in diabetic patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena